
A study of patients with stable ischemic heart disease, spanning up to 25 years, has cast doubt on the long-term benefits of widening narrowed coronary arteries.
While placing a stent in patients with stable ischemic heart disease restores blood flow, it does not necessarily lower the likelihood of a heart attack or premature death. This conclusion was reached by researchers led by Neal Butala from the University of Colorado Anschutz Medical Campus. The results of this long-term analysis were published in the journal JAMA and presented at the American Heart Association’s 2026 scientific sessions.
The researchers examined data from participants in the COURAGE trial, which compared two treatment approaches for stable coronary artery disease. Some patients received only optimal medical therapy, while others also underwent percutaneous coronary intervention—a procedure to widen an artery, typically involving the placement of a stent. As reported by SciTechDaily, the primary objective of this new analysis was to determine whether the initial intervention affects the long-term risk of cardiovascular complications.
The assessment included data on 959 patients, drawn from consolidated medical records. The median follow-up period was 15 years, with some participants monitored for as long as 25 years. The estimated probability of death or heart attack over 25 years was 93.3% for patients who initially received the intervention alongside medication, compared to 91% for the group that received medical therapy alone; however, no statistically significant difference was found between the two groups.
The authors emphasized that restoring blood flow and preventing future complications are distinct objectives. Angioplasty can reduce chest pain and other symptoms of the disease, but the findings did not confirm that it offers an advantage over medical therapy in lowering the overall risk of heart attack or death. This does not mean that stents are unnecessary; in certain types of heart attacks, urgent intervention can be life-saving. However, this specific analysis focused on the initial management strategy for patients in a stable condition.
The study was a follow-up of participants from a randomized trial, rather than a new randomized trial itself. The analysis included veterans whose medical records could be linked; consequently, their baseline health risks were higher than those of the broader COURAGE trial cohort. The researchers also noted potential challenges in identifying heart attacks based solely on routine medical records, yet the results were generally consistent with the clinical events verified by specialists during the original trial.
пециалистами во время первоначального испытания.